<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00812565</url>
  </required_header>
  <id_info>
    <org_study_id>GAM10-04</org_study_id>
    <nct_id>NCT00812565</nct_id>
  </id_info>
  <brief_title>Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>Prospective 24-week, Double-blind, Randomised, Placebo-controlled, Multicenter Study Evaluating Safety and Change in Efficacy-related Surrogate Parameters in Patients With Dementia of the Alzheimer's Type Under Treatment With Increasing Dosages of Intravenous Immunoglobulin (Octagam 10%)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the effect of 6 or 12 infusions of different doses of octagam
      (intravenous immunoglobulin [IVIG]) 10% on the reduction of amyloid beta peptide (Aβ) in
      cerebral spinal fluid (CSF) and on the increase of Aβ in blood plasma in patients with mild
      to moderate Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants received 12 infusions of 0.1 g/kg, 0.25 g/kg, or 0.4 g/kg body weight octagam
      10% at 2-week intervals (±3 days) or 6 infusions of 0.2 g/kg, 0.5 g/kg, or 0.8 g/kg body
      weight octagam 10% at 4-week intervals (±5 days). The effect of the infusions on the
      reduction of Aβ peptide in CSF and the increase of Aβ peptide in blood plasma was evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Area Under the Curve of Plasma Aβ1-40 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion</measure>
    <time_frame>Week 22 to Week 24 for participants who received infusions every 2 weeks and Week 20 to Week 24 participants who received infusions every 4 weeks</time_frame>
    <description>For participants who received infusions every 2 weeks, plasma samples were collected at the trough level at Week 22 and on Days 1, 4, 7, and 14 after Week 22. For participants who received infusions every 4 weeks, plasma samples were collected at the trough level at Week 20 and on Days 1, 4, 7, 14, 21, and 28 after Week 20. Samples for determining Aβ1-40 in blood plasma were processed at a central laboratory using a commercially available kit from Innogenetics NV (INNO-BIA plasma Aβ forms; Gent, Belgium).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Concentration of Aβ1-40 and Aβ1-42 From Baseline to the End of the Study (Week 24)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Samples for determining Aβ1-40 and Aβ1-42 in blood plasma were processed at a central laboratory using a commercially available kit from Innogenetics NV (INNO-BIA plasma Aβ forms; Gent, Belgium).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Concentration of Anti-Aβ Autoantibodies From Baseline to the End of the Study (Week 24)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Samples for determining anti-Aβ autoantibodies in blood plasma were processed at a central laboratory using a commercially available kit from DRG Instruments GmbH, (EIA-5099; Marburg, Germany) using methods established at the Department of Neurology, Philipps-University, Marburg, Germany (Professor Dr. med. Richard Dodel). The kit includes 6 standard concentrations of anti-Aβ antibody against which the results of the assay are compared. The standards contain 1, 5, 15, 30, 60, and 120 Relative Units (RTU) which contain 0.03, 0.17, 0.5, 1, 2, and 4 mg IgG/mL, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Area Under the Curve of Plasma Aβ1-42 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion</measure>
    <time_frame>Week 22 to Week 24 for participants who received infusions every 2 weeks and Week 20 to Week 24 participants who received infusions every 4 weeks</time_frame>
    <description>For participants who received infusions every 2 weeks, plasma samples were collected at the trough level at Week 22 and on Days 1, 4, 7, and 14 after Week 22. For participants who received infusions every 4 weeks, plasma samples were collected at the trough level at Week 20 and on Days 1, 4, 7, 14, 21, and 28 after Week 20. Samples for determining Aβ1-42 in blood plasma were processed at a central laboratory using a commercially available kit from Innogenetics NV (INNO-BIA plasma Aβ forms; Gent, Belgium).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Area Under the Curve of Plasma Anti-Aβ Autoantibodies in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion</measure>
    <time_frame>Week 22 to Week 24 for participants who received infusions every 2 weeks and Week 20 to Week 24 participants who received infusions every 4 weeks</time_frame>
    <description>For participants who received infusions every 2 weeks, plasma samples were collected at the trough level at Week 22 and on Days 1, 4, 7, and 14 after Week 22. For participants who received infusions every 4 weeks, plasma samples were collected at the trough level at Week 20 and on Days 1, 4, 7, 14, 21, and 28 after Week 20. Samples for determining anti-Aβ autoantibodies in blood plasma were processed at a central laboratory using a commercially available kit from DRG Instruments GmbH, (EIA-5099; Marburg, Germany) using methods established at the Department of Neurology, Philipps-University, Marburg, Germany (Professor Dr. med. Richard Dodel). The kit includes 6 standard concentrations of anti-Aβ antibody against which the results of the assay are compared. The standards contain 1, 5, 15, 30, 60, and 120 Relative Units (RTU) which contain 0.03, 0.17, 0.5, 1, 2, and 4 mg IgG/mL, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aβ1-40 and Aβ1-42 in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion</measure>
    <time_frame>Baseline to Week 23 Day 2 for participants who received infusions every 2 weeks and Baseline to Week 21 Day 2 for participants who received infusions every 4 weeks</time_frame>
    <description>Samples for determining Aβ1-40 and Aβ1-42 in cerebral spinal fluid were processed at a central laboratory using a commercially available kit from Meso Scale Discovery (MSD 96-Well Multi-Spot Human/Rodent (4G8) Abeta Triplex Ultra-Sensitive Assay; Rockville, MD, USA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Anti-Aβ Autoantibodies in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion</measure>
    <time_frame>Baseline to Week 23 Day 2 for participants who received infusions every 2 weeks and Baseline to Week 21 Day 2 for participants who received infusions every 4 weeks</time_frame>
    <description>Samples for determining anti-Aβ autoantibodies in blood plasma were processed at a central laboratory using a commercially available kit from DRG Instruments GmbH, (EIA-5099; Marburg, Germany) using methods established at the Department of Neurology, Philipps-University, Marburg, Germany (Professor Dr. med. Richard Dodel). The kit includes 6 standard concentrations of anti-Aβ antibody against which the results of the assay are compared. The standards contain 1, 5, 15, 30, 60, and 120 Relative Units (RTU) which contain 0.03, 0.17, 0.5, 1, 2, and 4 mg IgG/mL, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tau and Phosphorylated Tau in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion</measure>
    <time_frame>Baseline to Week 23 Day 2 for participants who received infusions every 2 weeks and Baseline to Week 21 Day 2 for participants who received infusions every 4 weeks</time_frame>
    <description>Samples for determining tau and phosphorylated tau in cerebral spinal fluid were processed at a central laboratory using commercially available kits from Innogenetics NV (INNOTEST® hTau Ag, INNOTEST PHOSPHO-TAU (181P); Gent, Belgium). To measure phosphorylated tau, tau phosphorylated at threonine 181 (pTau181) was determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mini Mental Status Examination (MMSE) Score at Week 12 and Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The MMSE test contains 30 questions that assess 8 cognitive domains (orientation to time, orientation to place, registration, attention and calculation, recall, language, repetition, and complex commands). The test is administered by a neuropsychologist, psychometrician, or certified study coordinator. The total score ranges from 0 (severe impairment) to 30 (no impairment), with a higher score indicating a better mental status. A positive change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Alzheimer's Disease Assessment Scale, Cognitive Part (ADAS Cog) Score at Week 12 and Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The ADAS cog consists of 11 items that assess cognitive areas that are often impaired in Alzheimer's disease, specifically learning (word list), naming (objects), following commands (1 to 5 elements), ideational praxis (mail a letter), constructional praxis (copy 4 figures), orientation (person, time and place), recognition memory (from a second word list), and remembering test instructions (from the recognition subtest). The test includes 3 additional subjective scales that assess spoken language ability, word finding difficulty, and comprehension. The test is administered by a neuropsychologist, psychometrician, or certified study coordinator. The total score ranges from 0 to 70 with a higher score indicating greater cognitive impairment. A negative change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADAS-ADL) Score at Week 12 and Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The ADAS-ADL consists of 23 questions that measure the ability of a person to perform basic activities of daily living, such as eating, walking, bathing, grooming, and dressing. The test is administered by a neuropsychologist, psychometrician, or certified study coordinator. The total score ranges from 0 to 78 with a lower score indicating more impaired ability. A positive change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Clinical Dementia Ratio, Sum of Boxes (CDR-SOB) Score at Week 12 and Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>A semi-structured interview was conducted by a physician, neuropsychologist, psychometrician, or certified study coordinator with the patient and a caregiver. Based on the results of the interview, the patient was rated on 6 domains of cognition and function: Memory, orientation, judgment/problem solving, community activities, home and hobbies, and personal care. Each domain is rated from 0 = no dementia; 0.5 = questionable dementia, mild cognitive impairment; 1 = mild dementia; 2 = moderate dementia; 3 = severe dementia. The total score ranges from 0 to 18 with a higher score indicating more dementia. A negative change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Screening in Whole Brain and Hippocampal Volume at Week 12 and Week 24</measure>
    <time_frame>Screening to Week 24</time_frame>
    <description>The volume of the whole brain and of the left and right hippocampus was measured using high-resolution structural coronal 3D heavily T1-weighted gradient-echo sequence magnetic resonance imaging. All evaluations were done centrally by Professor Frederik Barkhof at the Image Analysis Centre, VU Medical Center, Amsterdam, Netherlands. A negative change score indicates loss of brain volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left and Right Hippocampal Cerebral Glucose Metabolism at Baseline and at Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Cerebral glucose metabolism was measured in validated 3 dimensional statistic surface projection analysis (Cortex ID®, GE Healthcare), transversal/coronal/sagittal-slice analysis (HERMES BRASS), and voxel-wise whole brain analysis (SPM5) using [18F]fluorodeoxyglucose positron emission tomography.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo every 2 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1 g/kg octagam 10% every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25 g/kg octagam 10% every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4 g/kg octagam 10% every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo every 4 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2 g/kg octagam 10% every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 g/kg octagam 10% every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.8 g/kg octagam 10% every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Commercially available 0.9% isotonic sodium chloride solution.</description>
    <arm_group_label>Placebo every 2 weeks</arm_group_label>
    <arm_group_label>Placebo every 4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>octagam 10%</intervention_name>
    <description>octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.</description>
    <arm_group_label>0.1 g/kg octagam 10% every 2 weeks</arm_group_label>
    <arm_group_label>0.25 g/kg octagam 10% every 2 weeks</arm_group_label>
    <arm_group_label>0.4 g/kg octagam 10% every 2 weeks</arm_group_label>
    <arm_group_label>0.2 g/kg octagam 10% every 4 weeks</arm_group_label>
    <arm_group_label>0.5 g/kg octagam 10% every 4 weeks</arm_group_label>
    <arm_group_label>0.8 g/kg octagam 10% every 4 weeks</arm_group_label>
    <other_name>IVIG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Probable Alzheimer's Disease (AD) according to the National Institute of Neurological
             and Communicative Disorders and Stroke and the Alzheimer's Disease and Related
             Disorders Association (NINCDS-ADRDA) criteria.

          -  Age of 50 to 85.

          -  Mini-mental State Examination (MMSE) score of 16 to 26.

          -  Sufficient language skills for testing.

          -  Sufficient vision and hearing for testing.

          -  Modified Hachinski-Rosen Score &lt; 5.

          -  Magnetic resonance imaging (MRI) of the head consistent with the diagnosis of AD.

          -  Caregiver available with contact at least 4 days per week for greater than 1 hour.

          -  Outpatient status or assisted living.

          -  Post-menopause (women) as evidenced by lack of menstruation for at least 12
             consecutive months or by having bilateral oophorectomy.

          -  Stable doses of approved AD medication(s) for at least 3 months prior to screening
             (eg, acetylcholine esterase (AChE) inhibitors, memantine).

          -  Normal vital signs or clinically insignificant, if outside normal limits.

          -  Laboratory findings within normal limits or clinically insignificant, if outside
             normal limits.

          -  Normal electrocardiogram (ECG) or clinically not significant, if outside normal
             limits.

        Exclusion Criteria:

          -  Other causes of dementia (eg, vascular dementia, Lewy-body dementia, fronto-temporal
             dementia, Creutzfeldt-Jacob disease, Huntington's disease, Parkinson's disease).

          -  History of or present significant other diseases of the central nervous system (eg,
             brain tumor, normal pressure hydrocephalus, Parkinson's Disease, stroke, severe brain
             trauma, brain surgery, epilepsy, encephalitis).

          -  Geriatric depression scale score &gt; 7 (short form with scale from 0 to 15).

          -  Present significant psychiatric disorder (eg, major depression).

          -  History of psychosis or hallucinations.

          -  Mental retardation.

          -  Unstable medical disease in the opinion of the investigator.

          -  Insulin dependent diabetes mellitus.

          -  Acute infectious disease.

          -  Vitamin B12 deficiency unless on stable replacement therapy for at least 3 months is
             acceptable.

          -  Unstable thyroid dysfunction.

          -  Uncontrolled hypertension.

          -  Severe liver or kidney disease.

          -  Major surgery within 3 months prior to screening.

          -  Prohibited medications: Antiepileptic drugs, antipsychotics (but allowed for treatment
             of acute episodes), antiparkinson agents, anticholinergic drugs, selegiline, monoamine
             oxidase inhibitors (MAOI), tricyclics, immunosuppressive medications, anti-histamines
             (unless on a stable dose for at least 3 months or used for treatment of acute
             episodes), benzodiazepines (but allowed for treatment of acute episodes), and lithium.

          -  Antidepressants are permitted, if on a stable dose for at least 3 months and without
             significant anticholinergic side-effects.

          -  Peripheral venous conditions which impair establishing regular venous access for
             infusions.

          -  Potential reasons that patient may become non-evaluable during the study (eg, planned
             moving into a nursing home, but assisted living is acceptable).

          -  Peripheral venous conditions, which impair establishing regular venous access for
             infusions.

          -  Known IgA deficiency with antibodies to IgA.

          -  History of hypersensitivity to blood or plasma derived products, or any component of
             octagam 10%, such as maltose.

          -  Medical conditions which interfere with protein catabolism (eg, nephrotic syndrome).

          -  Known blood hyperviscosity or other hypercoagulable states.

          -  Deep vein thrombosis within preceding 4 years.

          -  Symptomatic stroke.

          -  Transient ischemic attack (TIA) within preceding 2 years.

          -  Participation in another drug trial within the previous 3 months before screening.

          -  Participation in immunological treatment studies of AD other than with intravenous
             immunoglobulin (IGIV) within the previous 6 months before screening.

          -  IGIV use in the previous 6 months.

          -  Live viral vaccination within the last month before study entry.

          -  Not eligible for lumbar puncture (anticoagulant therapy, coagulation disorders, severe
             spinal alterations).

          -  Patients with a past or present history of drug abuse or alcohol abuse within the
             preceding 5 years.

          -  Patients with any condition that would make the patient, in the opinion of the
             Investigator, unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Frenzel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Octapharma USA</name>
      <address>
        <city>Hoboken</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <results_first_submitted>December 2, 2013</results_first_submitted>
  <results_first_submitted_qc>April 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2014</results_first_posted>
  <last_update_submitted>April 2, 2014</last_update_submitted>
  <last_update_submitted_qc>April 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient was enrolled February 2, 2009. The last patient study visit was September 21, 2010. Patients were enrolled in this study from a variety of settings including private practice clinics and hospitals. There were 12 study sites, 5 in Germany and 7 in the United States.</recruitment_details>
      <pre_assignment_details>Qualified patients meeting all inclusion exclusion criteria and providing informed consent were enrolled into the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Every 2 Weeks</title>
          <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
        </group>
        <group group_id="P2">
          <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
          <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
        </group>
        <group group_id="P3">
          <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
          <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
        </group>
        <group group_id="P4">
          <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
          <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
        </group>
        <group group_id="P5">
          <title>Placebo Every 4 Weeks</title>
          <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
        </group>
        <group group_id="P6">
          <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
          <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
        </group>
        <group group_id="P7">
          <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
          <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
        </group>
        <group group_id="P8">
          <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
          <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did Not Receive Study Medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Come to Study Visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set: All randomized patients who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Every 2 Weeks</title>
          <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
        </group>
        <group group_id="B2">
          <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
          <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
        </group>
        <group group_id="B3">
          <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
          <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
        </group>
        <group group_id="B4">
          <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
          <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
        </group>
        <group group_id="B5">
          <title>Placebo Every 4 Weeks</title>
          <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
        </group>
        <group group_id="B6">
          <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
          <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
        </group>
        <group group_id="B7">
          <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
          <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
        </group>
        <group group_id="B8">
          <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
          <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="8"/>
            <count group_id="B8" value="7"/>
            <count group_id="B9" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.6" spread="9.2"/>
                    <measurement group_id="B2" value="66.8" spread="5.5"/>
                    <measurement group_id="B3" value="68.3" spread="4.2"/>
                    <measurement group_id="B4" value="72.9" spread="5.0"/>
                    <measurement group_id="B5" value="71.4" spread="11.8"/>
                    <measurement group_id="B6" value="74.8" spread="5.5"/>
                    <measurement group_id="B7" value="65.9" spread="10.2"/>
                    <measurement group_id="B8" value="68.4" spread="8.6"/>
                    <measurement group_id="B9" value="70.0" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Area Under the Curve of Plasma Aβ1-40 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion</title>
        <description>For participants who received infusions every 2 weeks, plasma samples were collected at the trough level at Week 22 and on Days 1, 4, 7, and 14 after Week 22. For participants who received infusions every 4 weeks, plasma samples were collected at the trough level at Week 20 and on Days 1, 4, 7, 14, 21, and 28 after Week 20. Samples for determining Aβ1-40 in blood plasma were processed at a central laboratory using a commercially available kit from Innogenetics NV (INNO-BIA plasma Aβ forms; Gent, Belgium).</description>
        <time_frame>Week 22 to Week 24 for participants who received infusions every 2 weeks and Week 20 to Week 24 participants who received infusions every 4 weeks</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Area Under the Curve of Plasma Aβ1-40 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion</title>
          <description>For participants who received infusions every 2 weeks, plasma samples were collected at the trough level at Week 22 and on Days 1, 4, 7, and 14 after Week 22. For participants who received infusions every 4 weeks, plasma samples were collected at the trough level at Week 20 and on Days 1, 4, 7, 14, 21, and 28 after Week 20. Samples for determining Aβ1-40 in blood plasma were processed at a central laboratory using a commercially available kit from Innogenetics NV (INNO-BIA plasma Aβ forms; Gent, Belgium).</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>(pg/mL)*days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.20" spread="93.90"/>
                    <measurement group_id="O2" value="-245.67" spread="747.58"/>
                    <measurement group_id="O3" value="-122.50" spread="478.31"/>
                    <measurement group_id="O4" value="-39.10" spread="172.72"/>
                    <measurement group_id="O5" value="510.92" spread="2395.80"/>
                    <measurement group_id="O6" value="-83.67" spread="957.69"/>
                    <measurement group_id="O7" value="-755.38" spread="2232.87"/>
                    <measurement group_id="O8" value="-262.92" spread="671.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Concentration of Aβ1-40 and Aβ1-42 From Baseline to the End of the Study (Week 24)</title>
        <description>Samples for determining Aβ1-40 and Aβ1-42 in blood plasma were processed at a central laboratory using a commercially available kit from Innogenetics NV (INNO-BIA plasma Aβ forms; Gent, Belgium).</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Concentration of Aβ1-40 and Aβ1-42 From Baseline to the End of the Study (Week 24)</title>
          <description>Samples for determining Aβ1-40 and Aβ1-42 in blood plasma were processed at a central laboratory using a commercially available kit from Innogenetics NV (INNO-BIA plasma Aβ forms; Gent, Belgium).</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aβ1-40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" spread="40.2"/>
                    <measurement group_id="O2" value="5.5" spread="64.5"/>
                    <measurement group_id="O3" value="-0.3" spread="22.1"/>
                    <measurement group_id="O4" value="-6.5" spread="61.4"/>
                    <measurement group_id="O5" value="-6.0" spread="23.8"/>
                    <measurement group_id="O6" value="-20.3" spread="29.2"/>
                    <measurement group_id="O7" value="15.7" spread="29.7"/>
                    <measurement group_id="O8" value="-30.5" spread="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aβ1-42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="3.8"/>
                    <measurement group_id="O2" value="-2.3" spread="7.8"/>
                    <measurement group_id="O3" value="-4.5" spread="6.3"/>
                    <measurement group_id="O4" value="-2.7" spread="7.6"/>
                    <measurement group_id="O5" value="-2.0" spread="4.8"/>
                    <measurement group_id="O6" value="-3.5" spread="5.8"/>
                    <measurement group_id="O7" value="-0.1" spread="4.4"/>
                    <measurement group_id="O8" value="-7.0" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Concentration of Anti-Aβ Autoantibodies From Baseline to the End of the Study (Week 24)</title>
        <description>Samples for determining anti-Aβ autoantibodies in blood plasma were processed at a central laboratory using a commercially available kit from DRG Instruments GmbH, (EIA-5099; Marburg, Germany) using methods established at the Department of Neurology, Philipps-University, Marburg, Germany (Professor Dr. med. Richard Dodel). The kit includes 6 standard concentrations of anti-Aβ antibody against which the results of the assay are compared. The standards contain 1, 5, 15, 30, 60, and 120 Relative Units (RTU) which contain 0.03, 0.17, 0.5, 1, 2, and 4 mg IgG/mL, respectively.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Concentration of Anti-Aβ Autoantibodies From Baseline to the End of the Study (Week 24)</title>
          <description>Samples for determining anti-Aβ autoantibodies in blood plasma were processed at a central laboratory using a commercially available kit from DRG Instruments GmbH, (EIA-5099; Marburg, Germany) using methods established at the Department of Neurology, Philipps-University, Marburg, Germany (Professor Dr. med. Richard Dodel). The kit includes 6 standard concentrations of anti-Aβ antibody against which the results of the assay are compared. The standards contain 1, 5, 15, 30, 60, and 120 Relative Units (RTU) which contain 0.03, 0.17, 0.5, 1, 2, and 4 mg IgG/mL, respectively.</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>RTU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.7" spread="284.8"/>
                    <measurement group_id="O2" value="74.3" spread="35.0"/>
                    <measurement group_id="O3" value="163.9" spread="136.6"/>
                    <measurement group_id="O4" value="310.2" spread="193.0"/>
                    <measurement group_id="O5" value="-56.3" spread="58.3"/>
                    <measurement group_id="O6" value="96.7" spread="133.7"/>
                    <measurement group_id="O7" value="256.6" spread="214.1"/>
                    <measurement group_id="O8" value="501.3" spread="514.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Area Under the Curve of Plasma Aβ1-42 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion</title>
        <description>For participants who received infusions every 2 weeks, plasma samples were collected at the trough level at Week 22 and on Days 1, 4, 7, and 14 after Week 22. For participants who received infusions every 4 weeks, plasma samples were collected at the trough level at Week 20 and on Days 1, 4, 7, 14, 21, and 28 after Week 20. Samples for determining Aβ1-42 in blood plasma were processed at a central laboratory using a commercially available kit from Innogenetics NV (INNO-BIA plasma Aβ forms; Gent, Belgium).</description>
        <time_frame>Week 22 to Week 24 for participants who received infusions every 2 weeks and Week 20 to Week 24 participants who received infusions every 4 weeks</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Area Under the Curve of Plasma Aβ1-42 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion</title>
          <description>For participants who received infusions every 2 weeks, plasma samples were collected at the trough level at Week 22 and on Days 1, 4, 7, and 14 after Week 22. For participants who received infusions every 4 weeks, plasma samples were collected at the trough level at Week 20 and on Days 1, 4, 7, 14, 21, and 28 after Week 20. Samples for determining Aβ1-42 in blood plasma were processed at a central laboratory using a commercially available kit from Innogenetics NV (INNO-BIA plasma Aβ forms; Gent, Belgium).</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>(pg/mL)*days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.70" spread="48.54"/>
                    <measurement group_id="O2" value="-8.92" spread="61.71"/>
                    <measurement group_id="O3" value="-53.94" spread="61.59"/>
                    <measurement group_id="O4" value="-17.00" spread="23.67"/>
                    <measurement group_id="O5" value="50.13" spread="233.87"/>
                    <measurement group_id="O6" value="-8.98" spread="213.29"/>
                    <measurement group_id="O7" value="-191.58" spread="456.83"/>
                    <measurement group_id="O8" value="-64.75" spread="148.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Area Under the Curve of Plasma Anti-Aβ Autoantibodies in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion</title>
        <description>For participants who received infusions every 2 weeks, plasma samples were collected at the trough level at Week 22 and on Days 1, 4, 7, and 14 after Week 22. For participants who received infusions every 4 weeks, plasma samples were collected at the trough level at Week 20 and on Days 1, 4, 7, 14, 21, and 28 after Week 20. Samples for determining anti-Aβ autoantibodies in blood plasma were processed at a central laboratory using a commercially available kit from DRG Instruments GmbH, (EIA-5099; Marburg, Germany) using methods established at the Department of Neurology, Philipps-University, Marburg, Germany (Professor Dr. med. Richard Dodel). The kit includes 6 standard concentrations of anti-Aβ antibody against which the results of the assay are compared. The standards contain 1, 5, 15, 30, 60, and 120 Relative Units (RTU) which contain 0.03, 0.17, 0.5, 1, 2, and 4 mg IgG/mL, respectively.</description>
        <time_frame>Week 22 to Week 24 for participants who received infusions every 2 weeks and Week 20 to Week 24 participants who received infusions every 4 weeks</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Area Under the Curve of Plasma Anti-Aβ Autoantibodies in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion</title>
          <description>For participants who received infusions every 2 weeks, plasma samples were collected at the trough level at Week 22 and on Days 1, 4, 7, and 14 after Week 22. For participants who received infusions every 4 weeks, plasma samples were collected at the trough level at Week 20 and on Days 1, 4, 7, 14, 21, and 28 after Week 20. Samples for determining anti-Aβ autoantibodies in blood plasma were processed at a central laboratory using a commercially available kit from DRG Instruments GmbH, (EIA-5099; Marburg, Germany) using methods established at the Department of Neurology, Philipps-University, Marburg, Germany (Professor Dr. med. Richard Dodel). The kit includes 6 standard concentrations of anti-Aβ antibody against which the results of the assay are compared. The standards contain 1, 5, 15, 30, 60, and 120 Relative Units (RTU) which contain 0.03, 0.17, 0.5, 1, 2, and 4 mg IgG/mL, respectively.</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>RTU*days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2829.0" spread="3957.9"/>
                    <measurement group_id="O2" value="358.3" spread="435.8"/>
                    <measurement group_id="O3" value="1862.5" spread="1470.9"/>
                    <measurement group_id="O4" value="2189.6" spread="2289.3"/>
                    <measurement group_id="O5" value="196.6" spread="1023.0"/>
                    <measurement group_id="O6" value="849.4" spread="2313.6"/>
                    <measurement group_id="O7" value="6350.8" spread="3464.9"/>
                    <measurement group_id="O8" value="8494.9" spread="2292.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aβ1-40 and Aβ1-42 in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion</title>
        <description>Samples for determining Aβ1-40 and Aβ1-42 in cerebral spinal fluid were processed at a central laboratory using a commercially available kit from Meso Scale Discovery (MSD 96-Well Multi-Spot Human/Rodent (4G8) Abeta Triplex Ultra-Sensitive Assay; Rockville, MD, USA).</description>
        <time_frame>Baseline to Week 23 Day 2 for participants who received infusions every 2 weeks and Baseline to Week 21 Day 2 for participants who received infusions every 4 weeks</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aβ1-40 and Aβ1-42 in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion</title>
          <description>Samples for determining Aβ1-40 and Aβ1-42 in cerebral spinal fluid were processed at a central laboratory using a commercially available kit from Meso Scale Discovery (MSD 96-Well Multi-Spot Human/Rodent (4G8) Abeta Triplex Ultra-Sensitive Assay; Rockville, MD, USA).</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aβ1-40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="939.4" spread="1670.8"/>
                    <measurement group_id="O2" value="266.7" spread="996.0"/>
                    <measurement group_id="O3" value="10.6" spread="1104.0"/>
                    <measurement group_id="O4" value="-147.0" spread="1067.9"/>
                    <measurement group_id="O5" value="42.0" spread="874.0"/>
                    <measurement group_id="O6" value="561.7" spread="1195.5"/>
                    <measurement group_id="O7" value="403.9" spread="588.1"/>
                    <measurement group_id="O8" value="642.2" spread="1171.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aβ1-42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="67.0"/>
                    <measurement group_id="O2" value="-8.7" spread="38.2"/>
                    <measurement group_id="O3" value="9.7" spread="54.7"/>
                    <measurement group_id="O4" value="4.0" spread="40.3"/>
                    <measurement group_id="O5" value="-5.2" spread="36.3"/>
                    <measurement group_id="O6" value="18.8" spread="40.3"/>
                    <measurement group_id="O7" value="10.5" spread="40.9"/>
                    <measurement group_id="O8" value="24.7" spread="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Anti-Aβ Autoantibodies in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion</title>
        <description>Samples for determining anti-Aβ autoantibodies in blood plasma were processed at a central laboratory using a commercially available kit from DRG Instruments GmbH, (EIA-5099; Marburg, Germany) using methods established at the Department of Neurology, Philipps-University, Marburg, Germany (Professor Dr. med. Richard Dodel). The kit includes 6 standard concentrations of anti-Aβ antibody against which the results of the assay are compared. The standards contain 1, 5, 15, 30, 60, and 120 Relative Units (RTU) which contain 0.03, 0.17, 0.5, 1, 2, and 4 mg IgG/mL, respectively.</description>
        <time_frame>Baseline to Week 23 Day 2 for participants who received infusions every 2 weeks and Baseline to Week 21 Day 2 for participants who received infusions every 4 weeks</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Anti-Aβ Autoantibodies in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion</title>
          <description>Samples for determining anti-Aβ autoantibodies in blood plasma were processed at a central laboratory using a commercially available kit from DRG Instruments GmbH, (EIA-5099; Marburg, Germany) using methods established at the Department of Neurology, Philipps-University, Marburg, Germany (Professor Dr. med. Richard Dodel). The kit includes 6 standard concentrations of anti-Aβ antibody against which the results of the assay are compared. The standards contain 1, 5, 15, 30, 60, and 120 Relative Units (RTU) which contain 0.03, 0.17, 0.5, 1, 2, and 4 mg IgG/mL, respectively.</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>RTU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="3.72"/>
                    <measurement group_id="O2" value="0.22" spread="1.83"/>
                    <measurement group_id="O3" value="1.86" spread="1.93"/>
                    <measurement group_id="O4" value="-0.78" spread="1.64"/>
                    <measurement group_id="O5" value="0.15" spread="0.29"/>
                    <measurement group_id="O6" value="0.40" spread="1.43"/>
                    <measurement group_id="O7" value="1.12" spread="1.48"/>
                    <measurement group_id="O8" value="0.74" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tau and Phosphorylated Tau in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion</title>
        <description>Samples for determining tau and phosphorylated tau in cerebral spinal fluid were processed at a central laboratory using commercially available kits from Innogenetics NV (INNOTEST® hTau Ag, INNOTEST PHOSPHO-TAU (181P); Gent, Belgium). To measure phosphorylated tau, tau phosphorylated at threonine 181 (pTau181) was determined.</description>
        <time_frame>Baseline to Week 23 Day 2 for participants who received infusions every 2 weeks and Baseline to Week 21 Day 2 for participants who received infusions every 4 weeks</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tau and Phosphorylated Tau in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion</title>
          <description>Samples for determining tau and phosphorylated tau in cerebral spinal fluid were processed at a central laboratory using commercially available kits from Innogenetics NV (INNOTEST® hTau Ag, INNOTEST PHOSPHO-TAU (181P); Gent, Belgium). To measure phosphorylated tau, tau phosphorylated at threonine 181 (pTau181) was determined.</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="38.6"/>
                    <measurement group_id="O2" value="209.3" spread="416.0"/>
                    <measurement group_id="O3" value="-3.4" spread="35.6"/>
                    <measurement group_id="O4" value="-7.8" spread="51.3"/>
                    <measurement group_id="O5" value="-33.2" spread="69.7"/>
                    <measurement group_id="O6" value="-141.8" spread="419.5"/>
                    <measurement group_id="O7" value="1.3" spread="86.7"/>
                    <measurement group_id="O8" value="131.3" spread="301.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorylated tau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="7.50"/>
                    <measurement group_id="O2" value="-3.17" spread="14.66"/>
                    <measurement group_id="O3" value="0.43" spread="3.60"/>
                    <measurement group_id="O4" value="2.60" spread="4.98"/>
                    <measurement group_id="O5" value="-1.33" spread="10.05"/>
                    <measurement group_id="O6" value="3.33" spread="21.23"/>
                    <measurement group_id="O7" value="-2.50" spread="8.62"/>
                    <measurement group_id="O8" value="10.17" spread="19.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mini Mental Status Examination (MMSE) Score at Week 12 and Week 24</title>
        <description>The MMSE test contains 30 questions that assess 8 cognitive domains (orientation to time, orientation to place, registration, attention and calculation, recall, language, repetition, and complex commands). The test is administered by a neuropsychologist, psychometrician, or certified study coordinator. The total score ranges from 0 (severe impairment) to 30 (no impairment), with a higher score indicating a better mental status. A positive change score indicates improvement.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mini Mental Status Examination (MMSE) Score at Week 12 and Week 24</title>
          <description>The MMSE test contains 30 questions that assess 8 cognitive domains (orientation to time, orientation to place, registration, attention and calculation, recall, language, repetition, and complex commands). The test is administered by a neuropsychologist, psychometrician, or certified study coordinator. The total score ranges from 0 (severe impairment) to 30 (no impairment), with a higher score indicating a better mental status. A positive change score indicates improvement.</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=6,6,7,5,7,6,8,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.1"/>
                    <measurement group_id="O2" value="-2.3" spread="3.5"/>
                    <measurement group_id="O3" value="-0.6" spread="3.0"/>
                    <measurement group_id="O4" value="-2.0" spread="3.1"/>
                    <measurement group_id="O5" value="-0.7" spread="3.0"/>
                    <measurement group_id="O6" value="-1.2" spread="2.3"/>
                    <measurement group_id="O7" value="-0.3" spread="2.8"/>
                    <measurement group_id="O8" value="-0.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=7,6,7,6,6,6,8,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="3.0"/>
                    <measurement group_id="O2" value="-2.2" spread="4.4"/>
                    <measurement group_id="O3" value="0.6" spread="2.5"/>
                    <measurement group_id="O4" value="-1.7" spread="2.3"/>
                    <measurement group_id="O5" value="-1.8" spread="5.5"/>
                    <measurement group_id="O6" value="-3.2" spread="3.3"/>
                    <measurement group_id="O7" value="-1.8" spread="1.8"/>
                    <measurement group_id="O8" value="-1.5" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Alzheimer’s Disease Assessment Scale, Cognitive Part (ADAS Cog) Score at Week 12 and Week 24</title>
        <description>The ADAS cog consists of 11 items that assess cognitive areas that are often impaired in Alzheimer’s disease, specifically learning (word list), naming (objects), following commands (1 to 5 elements), ideational praxis (mail a letter), constructional praxis (copy 4 figures), orientation (person, time and place), recognition memory (from a second word list), and remembering test instructions (from the recognition subtest). The test includes 3 additional subjective scales that assess spoken language ability, word finding difficulty, and comprehension. The test is administered by a neuropsychologist, psychometrician, or certified study coordinator. The total score ranges from 0 to 70 with a higher score indicating greater cognitive impairment. A negative change score indicates improvement.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Alzheimer’s Disease Assessment Scale, Cognitive Part (ADAS Cog) Score at Week 12 and Week 24</title>
          <description>The ADAS cog consists of 11 items that assess cognitive areas that are often impaired in Alzheimer’s disease, specifically learning (word list), naming (objects), following commands (1 to 5 elements), ideational praxis (mail a letter), constructional praxis (copy 4 figures), orientation (person, time and place), recognition memory (from a second word list), and remembering test instructions (from the recognition subtest). The test includes 3 additional subjective scales that assess spoken language ability, word finding difficulty, and comprehension. The test is administered by a neuropsychologist, psychometrician, or certified study coordinator. The total score ranges from 0 to 70 with a higher score indicating greater cognitive impairment. A negative change score indicates improvement.</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=6,6,7,5,7,6,8,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="4.10"/>
                    <measurement group_id="O2" value="0.94" spread="7.27"/>
                    <measurement group_id="O3" value="-0.86" spread="4.75"/>
                    <measurement group_id="O4" value="-0.07" spread="4.43"/>
                    <measurement group_id="O5" value="1.52" spread="5.67"/>
                    <measurement group_id="O6" value="3.67" spread="3.85"/>
                    <measurement group_id="O7" value="1.54" spread="6.63"/>
                    <measurement group_id="O8" value="2.28" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=7,6,7,6,5,6,8,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="3.86"/>
                    <measurement group_id="O2" value="2.06" spread="3.32"/>
                    <measurement group_id="O3" value="-2.14" spread="4.41"/>
                    <measurement group_id="O4" value="3.67" spread="4.85"/>
                    <measurement group_id="O5" value="0.93" spread="3.29"/>
                    <measurement group_id="O6" value="4.17" spread="4.85"/>
                    <measurement group_id="O7" value="3.00" spread="9.37"/>
                    <measurement group_id="O8" value="1.89" spread="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADAS-ADL) Score at Week 12 and Week 24</title>
        <description>The ADAS-ADL consists of 23 questions that measure the ability of a person to perform basic activities of daily living, such as eating, walking, bathing, grooming, and dressing. The test is administered by a neuropsychologist, psychometrician, or certified study coordinator. The total score ranges from 0 to 78 with a lower score indicating more impaired ability. A positive change score indicates improvement.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADAS-ADL) Score at Week 12 and Week 24</title>
          <description>The ADAS-ADL consists of 23 questions that measure the ability of a person to perform basic activities of daily living, such as eating, walking, bathing, grooming, and dressing. The test is administered by a neuropsychologist, psychometrician, or certified study coordinator. The total score ranges from 0 to 78 with a lower score indicating more impaired ability. A positive change score indicates improvement.</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=6,6,7,5,7,6,8,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="4.0"/>
                    <measurement group_id="O2" value="0.0" spread="5.4"/>
                    <measurement group_id="O3" value="1.7" spread="2.8"/>
                    <measurement group_id="O4" value="-1.2" spread="3.5"/>
                    <measurement group_id="O5" value="-0.6" spread="8.5"/>
                    <measurement group_id="O6" value="-8.2" spread="11.8"/>
                    <measurement group_id="O7" value="1.8" spread="5.0"/>
                    <measurement group_id="O8" value="-1.9" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=7,6,7,6,5,6,8,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="5.0"/>
                    <measurement group_id="O2" value="-1.5" spread="5.2"/>
                    <measurement group_id="O3" value="-4.1" spread="6.6"/>
                    <measurement group_id="O4" value="-6.5" spread="9.7"/>
                    <measurement group_id="O5" value="-1.8" spread="6.0"/>
                    <measurement group_id="O6" value="-4.3" spread="14.4"/>
                    <measurement group_id="O7" value="1.5" spread="8.2"/>
                    <measurement group_id="O8" value="-1.2" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Clinical Dementia Ratio, Sum of Boxes (CDR-SOB) Score at Week 12 and Week 24</title>
        <description>A semi-structured interview was conducted by a physician, neuropsychologist, psychometrician, or certified study coordinator with the patient and a caregiver. Based on the results of the interview, the patient was rated on 6 domains of cognition and function: Memory, orientation, judgment/problem solving, community activities, home and hobbies, and personal care. Each domain is rated from 0 = no dementia; 0.5 = questionable dementia, mild cognitive impairment; 1 = mild dementia; 2 = moderate dementia; 3 = severe dementia. The total score ranges from 0 to 18 with a higher score indicating more dementia. A negative change score indicates improvement.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Clinical Dementia Ratio, Sum of Boxes (CDR-SOB) Score at Week 12 and Week 24</title>
          <description>A semi-structured interview was conducted by a physician, neuropsychologist, psychometrician, or certified study coordinator with the patient and a caregiver. Based on the results of the interview, the patient was rated on 6 domains of cognition and function: Memory, orientation, judgment/problem solving, community activities, home and hobbies, and personal care. Each domain is rated from 0 = no dementia; 0.5 = questionable dementia, mild cognitive impairment; 1 = mild dementia; 2 = moderate dementia; 3 = severe dementia. The total score ranges from 0 to 18 with a higher score indicating more dementia. A negative change score indicates improvement.</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=6,6,7,5,7,6,8,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="1.08"/>
                    <measurement group_id="O2" value="-0.25" spread="0.76"/>
                    <measurement group_id="O3" value="0.21" spread="0.86"/>
                    <measurement group_id="O4" value="0.60" spread="0.89"/>
                    <measurement group_id="O5" value="-0.36" spread="1.38"/>
                    <measurement group_id="O6" value="0.42" spread="1.36"/>
                    <measurement group_id="O7" value="0.50" spread="1.46"/>
                    <measurement group_id="O8" value="0.21" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=7,6,7,6,5,6,8,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="1.57"/>
                    <measurement group_id="O2" value="0.92" spread="2.15"/>
                    <measurement group_id="O3" value="0.14" spread="1.28"/>
                    <measurement group_id="O4" value="1.25" spread="1.97"/>
                    <measurement group_id="O5" value="-1.50" spread="2.55"/>
                    <measurement group_id="O6" value="0.83" spread="1.44"/>
                    <measurement group_id="O7" value="0.44" spread="1.92"/>
                    <measurement group_id="O8" value="0.58" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Screening in Whole Brain and Hippocampal Volume at Week 12 and Week 24</title>
        <description>The volume of the whole brain and of the left and right hippocampus was measured using high-resolution structural coronal 3D heavily T1-weighted gradient-echo sequence magnetic resonance imaging. All evaluations were done centrally by Professor Frederik Barkhof at the Image Analysis Centre, VU Medical Center, Amsterdam, Netherlands. A negative change score indicates loss of brain volume.</description>
        <time_frame>Screening to Week 24</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Screening in Whole Brain and Hippocampal Volume at Week 12 and Week 24</title>
          <description>The volume of the whole brain and of the left and right hippocampus was measured using high-resolution structural coronal 3D heavily T1-weighted gradient-echo sequence magnetic resonance imaging. All evaluations were done centrally by Professor Frederik Barkhof at the Image Analysis Centre, VU Medical Center, Amsterdam, Netherlands. A negative change score indicates loss of brain volume.</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Whole brain - Week 12 (n=5,5,7,4,7,6,7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.112" spread="0.738"/>
                    <measurement group_id="O2" value="-0.548" spread="1.001"/>
                    <measurement group_id="O3" value="-0.709" spread="1.026"/>
                    <measurement group_id="O4" value="-1.833" spread="2.001"/>
                    <measurement group_id="O5" value="0.533" spread="0.481"/>
                    <measurement group_id="O6" value="-0.528" spread="1.873"/>
                    <measurement group_id="O7" value="-0.177" spread="1.219"/>
                    <measurement group_id="O8" value="-1.109" spread="0.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left hippocampus - Week 12 (n=5,6,7,5,7,6,7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="2.7"/>
                    <measurement group_id="O2" value="-3.1" spread="3.1"/>
                    <measurement group_id="O3" value="-2.4" spread="1.7"/>
                    <measurement group_id="O4" value="-1.8" spread="4.2"/>
                    <measurement group_id="O5" value="-2.8" spread="2.6"/>
                    <measurement group_id="O6" value="-2.8" spread="3.9"/>
                    <measurement group_id="O7" value="-4.8" spread="5.0"/>
                    <measurement group_id="O8" value="-2.2" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right hippocampus - Week 12 (n=5,6,7,5,7,6,7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="2.7"/>
                    <measurement group_id="O2" value="-2.6" spread="3.8"/>
                    <measurement group_id="O3" value="-3.6" spread="2.6"/>
                    <measurement group_id="O4" value="-3.0" spread="2.4"/>
                    <measurement group_id="O5" value="-4.8" spread="4.2"/>
                    <measurement group_id="O6" value="-1.8" spread="1.6"/>
                    <measurement group_id="O7" value="-1.5" spread="3.6"/>
                    <measurement group_id="O8" value="-4.9" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole brain - Week 24 (n=4,5,6,5,4,6,8,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.403" spread="0.978"/>
                    <measurement group_id="O2" value="-1.978" spread="0.798"/>
                    <measurement group_id="O3" value="-1.488" spread="0.726"/>
                    <measurement group_id="O4" value="-1.390" spread="1.678"/>
                    <measurement group_id="O5" value="-0.875" spread="0.780"/>
                    <measurement group_id="O6" value="-1.363" spread="1.752"/>
                    <measurement group_id="O7" value="-1.096" spread="1.004"/>
                    <measurement group_id="O8" value="-1.583" spread="1.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left hippocampus - Week 24 (n=4,6,6,5,5,6,8,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="3.8"/>
                    <measurement group_id="O2" value="-6.6" spread="3.0"/>
                    <measurement group_id="O3" value="-6.0" spread="2.8"/>
                    <measurement group_id="O4" value="-5.2" spread="4.1"/>
                    <measurement group_id="O5" value="-6.0" spread="5.0"/>
                    <measurement group_id="O6" value="-7.4" spread="4.3"/>
                    <measurement group_id="O7" value="-6.9" spread="7.7"/>
                    <measurement group_id="O8" value="-6.2" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right hippocampus - Week 24 (n=4,6,6,5,5,6,8,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="1.2"/>
                    <measurement group_id="O2" value="-4.4" spread="4.7"/>
                    <measurement group_id="O3" value="-6.3" spread="5.6"/>
                    <measurement group_id="O4" value="-4.5" spread="7.1"/>
                    <measurement group_id="O5" value="-5.1" spread="4.5"/>
                    <measurement group_id="O6" value="-5.3" spread="2.4"/>
                    <measurement group_id="O7" value="-6.5" spread="4.6"/>
                    <measurement group_id="O8" value="-8.2" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left and Right Hippocampal Cerebral Glucose Metabolism at Baseline and at Week 24</title>
        <description>Cerebral glucose metabolism was measured in validated 3 dimensional statistic surface projection analysis (Cortex ID®, GE Healthcare), transversal/coronal/sagittal-slice analysis (HERMES BRASS), and voxel-wise whole brain analysis (SPM5) using [18F]fluorodeoxyglucose positron emission tomography.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Every 2 Weeks</title>
            <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O2">
            <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O3">
            <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O4">
            <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
            <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Every 4 Weeks</title>
            <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O6">
            <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O7">
            <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
          <group group_id="O8">
            <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
            <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
          </group>
        </group_list>
        <measure>
          <title>Left and Right Hippocampal Cerebral Glucose Metabolism at Baseline and at Week 24</title>
          <description>Cerebral glucose metabolism was measured in validated 3 dimensional statistic surface projection analysis (Cortex ID®, GE Healthcare), transversal/coronal/sagittal-slice analysis (HERMES BRASS), and voxel-wise whole brain analysis (SPM5) using [18F]fluorodeoxyglucose positron emission tomography.</description>
          <population>Full analysis set: All randomized participants who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment. Only participants with available data were included in the analysis.</population>
          <units>µCi/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right hippocampus - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.06"/>
                    <measurement group_id="O2" value="0.81" spread="0.06"/>
                    <measurement group_id="O3" value="0.81" spread="0.06"/>
                    <measurement group_id="O4" value="0.83" spread="0.06"/>
                    <measurement group_id="O5" value="0.81" spread="0.08"/>
                    <measurement group_id="O6" value="0.88" spread="0.03"/>
                    <measurement group_id="O7" value="0.82" spread="0.08"/>
                    <measurement group_id="O8" value="0.81" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right hippocampus - Week 24 (n=6,6,6,5,3,6,8,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.07"/>
                    <measurement group_id="O2" value="0.83" spread="0.07"/>
                    <measurement group_id="O3" value="0.83" spread="0.06"/>
                    <measurement group_id="O4" value="0.81" spread="0.02"/>
                    <measurement group_id="O5" value="0.82" spread="0.07"/>
                    <measurement group_id="O6" value="0.87" spread="0.04"/>
                    <measurement group_id="O7" value="0.84" spread="0.07"/>
                    <measurement group_id="O8" value="0.82" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left hippocampus - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.05"/>
                    <measurement group_id="O2" value="0.77" spread="0.06"/>
                    <measurement group_id="O3" value="0.80" spread="0.07"/>
                    <measurement group_id="O4" value="0.81" spread="0.05"/>
                    <measurement group_id="O5" value="0.81" spread="0.07"/>
                    <measurement group_id="O6" value="0.84" spread="0.05"/>
                    <measurement group_id="O7" value="0.80" spread="0.06"/>
                    <measurement group_id="O8" value="0.77" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left hippocampus - Week 24 (n=6,6,6,5,3,6,8,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.03"/>
                    <measurement group_id="O2" value="0.78" spread="0.05"/>
                    <measurement group_id="O3" value="0.84" spread="0.09"/>
                    <measurement group_id="O4" value="0.80" spread="0.07"/>
                    <measurement group_id="O5" value="0.81" spread="0.08"/>
                    <measurement group_id="O6" value="0.84" spread="0.05"/>
                    <measurement group_id="O7" value="0.81" spread="0.05"/>
                    <measurement group_id="O8" value="0.79" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored throughout the entire study period, starting from the baseline visit until the final study visit.</time_frame>
      <desc>Safety set: All randomized participants who received at least 1 infusion of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Every 2 Weeks</title>
          <description>Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
        </group>
        <group group_id="E2">
          <title>0.1 g/kg Octagam 10% Every 2 Weeks</title>
          <description>Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).</description>
        </group>
        <group group_id="E3">
          <title>0.25 g/kg Octagam 10% Every 2 Weeks</title>
          <description>Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
        </group>
        <group group_id="E4">
          <title>0.4 g/kg Octagam 10% Every 2 Weeks</title>
          <description>Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).</description>
        </group>
        <group group_id="E5">
          <title>Placebo Every 4 Weeks</title>
          <description>Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
        </group>
        <group group_id="E6">
          <title>0.2 g/kg Octagam 10% Every 4 Weeks</title>
          <description>Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).</description>
        </group>
        <group group_id="E7">
          <title>0.5 g/kg Octagam 10% Every 4 Weeks</title>
          <description>Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
        </group>
        <group group_id="E8">
          <title>0.8 g/kg Octagam 10% Every 4 Weeks</title>
          <description>Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastral antral vascular ectasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's Type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Iron deficiency anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Submandibular mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anxiety postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Post procedural constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procedural headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procedural hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood iron decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>CSF white blood cell count positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Essential tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyporeflexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blood pressure fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vasoconstriction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small numbers of patients per treatment group (between 5 and 8) and variable total Aβ levels over time.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Eppolito, Director, Clinical Operations Immunology and ICU Medicine</name_or_title>
      <organization>Octapharma USA</organization>
      <phone>201-604-1155</phone>
      <email>michael.eppolito@octapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

